Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 87 across all filing types
Latest filing 2026-05-14 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing the company’s alterations in issued and treasury shares, including on-market share repurchases and treasury share sales. This is a regulatory disclosure of the issuer’s own share transactions, matching the definition for ‘Transaction in Own Shares’ (POS).
2026-05-14 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules detailing changes in issued shares and treasury shares, including specific line items on repurchases, closing balances, aggregate repurchase prices and on-market sales of treasury shares. This is a transaction report of the company buying back its own shares and holding treasury shares. It clearly falls under “Transaction in Own Shares” rather than a general capital issuance announcement or other category.
2026-05-13 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares and treasury shares, specifically share repurchases and on-market sales of treasury shares under Main Board Rule 13.25A/10.06. It contains a detailed repurchase report (Section II) with trading date, number of shares repurchased, method, and prices, which matches the definition of a Transaction in Own Shares. Not a high-level report or announcement but the actual transaction report for share buybacks/treasury movements.
2026-05-12 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 92% confidence The document is a ‘Next Day Disclosure Return’ under Hong Kong Stock Exchange rules detailing changes in issued shares, treasury share buybacks, on‐market repurchases, and related confirmations. This is a disclosure of the company’s own share transactions (buybacks/treasury sales), which matches the ‘Transaction in Own Shares’ category (POS).
2026-05-11 English
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2026-05-08 English
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2026-05-07 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.